Comparison of Mirabegron plus Tamsulosin and Tamsulosin Monotherapy for the Treatment of Ureteral Stent-Related Symptoms: A Prospective Randomized Study

Zhang K.a· Yan W.b· Li H.a· Chen J.a· Wang Q.a· Chai Y.a· Yuan L.a· Zhu G.a

Author affiliations

aDepartment of Urology, Beijing United Family Hospital and Clinics, Beijing, China
bDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: April 13, 2022
Accepted: August 13, 2022
Published online: October 14, 2022

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Abstract

Introduction: The aim of this study was to compare the efficacy of mirabegron plus tamsulosin to tamsulosin monotherapy in terms of ureteral stent-related discomfort after ureteroscopic lithotripsy. Methods: A total of 102 patients undergoing ureteroscopic lithotripsy and silicone ureteral stent placement were enrolled in this study. Patients were randomized 1:1 to receive either tamsulosin 0.4 mg once daily or mirabegron 50 mg + tamsulosin 0.4 mg once daily during the stenting period. Before the operation, the IPSS, QOL, and pain score were collected. On the day of ureteral stent removal, the USSQ, analgesic usage amount was collected and recorded. Results: The median USSQ-body pain score in the tamsulosin group and tamsulosin + mirabegron group was 15 and 16, respectively (p = 0.530). The median analgesic usage in the two groups was 3 and 2, respectively (p = 0.170). The median USSQ-urinary symptoms, USSQ-general health, USSQ-work performance, USSQ-sexual matters, and USSQ-additional problems in the two groups were 26 and 26 (p = 0.194), 11 and 12 (p = 0.068), 12 and 13 (p = 0.105), 2 and 2 (p = 0.437), 9 and 9 (p = 0.533), respectively. The international patients used more analgesics than Chinese patients (6 vs. 1, p = 0.015). Conclusion: Compared to tamsulosin alone, tamsulosin + mirabegron showed no additional benefit on the ureteral stent-related pain control after ureteroscopic lithotripsy and silicone stent placement. There was no significant difference on the analgesic usage and USSQ scores between the two groups. Chinese patients request fewer analgesics than international patients.

© 2022 S. Karger AG, Basel

References Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003;169(3):1065–9; discussion 1069. Bosio A, Alessandria E, Dalmasso E, Peretti D, Agosti S, Bisconti A, et al. How bothersome double-J ureteral stents are after semirigid and flexible ureteroscopy: a prospective single-institution observational study. World J Urol. 2019;37(1):201–7. Beysens M, Tailly TO. Ureteral stents in urolithiasis. Asian J Urol. 2018;5(4):274–86. Chen YB, Gao L, Jiang Q, Ran K, Luo RT. Tamsulosin monotherapy is effective in reducing ureteral stent-related symptoms: a meta-analysis of Randomized Controlled Studies. Curr Med Sci. 2019;39(5):707–18. Hadibrata E, Farishal A, Ali Z, Danarto R. Tamsulosin and sodium diclofenac as an effective therapy to reduce pain after ureteral stent removal: a prospective, double blinded randomized placebo controlled trial. Urol J. 2020;18(1):111–6. Kwon JK, Cho KS, Oh CK, Kang DH, Lee H, Ham WS, et al. The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo. BMC Urol. 2015;15:55. Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–33. Kaplan SA, Herschorn S, McVary KT, Staskin D, Chapple C, Foley S, et al. Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a Randomized, Phase 4 Study (PLUS). J Urol. 2020;203(6):1163–71. Tae BS, Cho S, Jeon BJ, Choi H, Park JY, Cho SY, et al. Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study. BJU Int. 2018;122(5):866–72. Olvera-Posada D, Suárez-Santos M, Castillejos-Molina R, Gabilondo-Navarro F, Méndez-Probst CE. Validation of the Spanish version of ureteral stent symptom questionnaire: prevalence of symptoms in a tertiary care center in Mexico. J Endourol. 2014;28(3):377–82. Abt D, Dötzer K, Honek P, Müller K, Engeler DS, Burger M, et al. The German linguistic validation of the Ureteral Stent Symptoms Questionnaire (USSQ). World J Urol. 2017;35(3):443–7. Zhu C, Qu J, Yang L, Feng X. The Chinese linguistic validation of the ureteral stent symptom questionnaire. Urol Int. 2019;102(2):194–8. Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr., Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003;169(3):1060–4. Turk An C, Petric A, et al. EAU Guidelines on Urolithiasis: 2020 version. 2020. Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res. 2009;37(3):147–52. Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ. Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort. BJU Int. 2011;108(11):1894–902. Gadzhiev N, Gorelov D, Malkhasyan V, Akopyan G, Harchelava R, Mazurenko D, et al. Comparison of silicone versus polyurethane ureteral stents: a prospective controlled study. BMC Urol. 2020;20(1):10. Wiseman O, Ventimiglia E, Doizi S, Kleinclauss F, Letendre J, Cloutier J, et al. Effects of silicone hydrocoated double loop ureteral stent on symptoms and quality of life in patients undergoing flexible ureteroscopy for kidney stone: a Randomized Multicenter Clinical Study. J Urol. 2020;204(4):769–77. Chen LM, Miaskowski C, Dodd M, Pantilat S. Concepts within the Chinese culture that influence the cancer pain experience. Cancer Nurs. 2008;31(2):103–8. Lasch KE. Culture, pain, and culturally sensitive pain care. Pain Manag Nurs. 2000;1(3 Suppl 1):16–22. Nakamura N, Ialomiteanu A, Rehm J, Fischer B. Prevalence and characteristics of substance use among Chinese and south Asians in Canada. J Ethn Subst Abuse. 2011;10(1):39–47. Matani YS, Al-Ghazo MA, Al-azab RS, Bani-hani O, Rabadi DK. Emergency double-J stent insertion following uncomplicated Ureteroscopy: risk-factor analysis and recommendations. Int Braz J Urol. 2013;39(2):203–8. Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: April 13, 2022
Accepted: August 13, 2022
Published online: October 14, 2022

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif